Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 7/20 | 0.41 |
| ▸ | XIAP | P98170 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.40 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.40 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22127789 | 0.90 | TSHR (0.48) | ELANEXIAPRAB9AITGB1ITGA4 | |
| SCHEMBL22127786 | 0.90 | TSHR (0.48) | ELANEXIAPRAB9AITGB1ITGA4 | |
| SCHEMBL19138290 | 0.85 | CAPN1 (0.51) | ELANEXIAPCAPN1CTSBPOLB | |
| SCHEMBL19138358 | 0.85 | CAPN1 (0.51) | ELANEXIAPCAPN1CTSBPOLB | |
| SCHEMBL19138289 | 0.85 | CAPN1 (0.51) | ELANEXIAPCAPN1CTSBPOLB | |
| SCHEMBL20993806 | 0.84 | POLB (0.53) | POLB | |
| SCHEMBL16529713 | 0.81 | ACE (0.44) | XIAPRAB9ATSHRCYP2C19 | |
| SCHEMBL19138322 | 0.81 | CAPN1 (0.57) | ELANEXIAPCAPN1CTSB | |
| SCHEMBL19138298 | 0.81 | CAPN1 (0.57) | ELANEXIAPCAPN1CTSB | |
| SCHEMBL19138297 | 0.81 | CAPN1 (0.57) | ELANEXIAPCAPN1CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180325893-A1 | SUBACUTE ADMINISTRATION OF NMDA MODULATORS ALONE OR IN COMBINATION | UNIV NORTHWESTERN (US) | 2018-11-15 | — | — | US | disclosed |
| US-20180237474-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | INNOVIVA TRC HOLDINGS LLC | 2018-08-23 | — | — | US | disclosed |
| US-20150315237-A1 | NMDA Receptor Modulators and Uses Thereof | NORTHWESTERN UNIVERSITY | 2015-11-05 | — | — | US | disclosed |
| US-20150051262-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | NORTHWESTERN UNIVERSITY (US) | 2015-02-19 | — | — | US | disclosed |
| US-8673843-B2 | NMDA receptors modulators and uses thereof | NORTHWESTERN UNIVERSITY (US) | 2014-03-18 | — | — | US | disclosed |
| US-20130035292-A1 | NMDA Receptors Modulators and Uses Thereof | INNOVIVA TRC HOLDINGS LLC | 2013-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051262-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | ELANE 3416/4885XIAP 2796/4885RAB9A 2220/4885 |
| US-20150315237-A1 | NMDA Receptor Modulators and Uses Thereof | GRIN1, GRIN2A, GRIN3A | ELANE 3416/4885XIAP 2796/4885RAB9A 2220/4885 |
| US-20180325893-A1 | SUBACUTE ADMINISTRATION OF NMDA MODULATORS ALONE OR IN COMBINATION | GRIN2A, GRIN2D, GRIN1 | ELANE 4611/4885XIAP 2606/4885RAB9A 2032/4885 |
| US-20180237474-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | ELANE 3416/4885XIAP 2796/4885RAB9A 2220/4885 |
| US-20130035292-A1 | NMDA Receptors Modulators and Uses Thereof | GRIN1, GRIN2A, GRIN3A | ELANE 3293/4885XIAP 2736/4885RAB9A 2239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.